Choo, Joan
Kua, Ley Fang
Soe, Mu Yar
Asuncion, Bernadette Reyna
Tan, Benjamin Kye Jyn
Teo, Chong Boon
Tay, Ryan Yong Kiat
So, Jimmy
Shabbir, Asim
Guowei, Kim
Tan, Hon Lyn
Chan, Gloria
Ma, Haoran
Ramachandran, Gokula Krishnan
Lum, Jeffrey H. Y.
Chee, Cheng Ean
Sridharan, Sriram
Tan, Patrick
Sundar, Raghav
Yong, Wei Peng
Funding for this research was provided by:
National Medical Research Council Singapore (OFLCG18May-0023, CGAug16M005)
Article History
Received: 2 June 2022
Accepted: 11 January 2023
First Online: 12 February 2023
Declarations
:
: WPY has received Honoraria and consulting fees from Abbvie/Genentech, Amgen, AstraZeneca, Bristol Myers Squibb, Ipsen, Novartis, Bayer, Eisai, Lilly, MSD, Sanofi/Aventis and Taiho Pharmaceutical. RS has received Honoraria from Bristol Myers Squibb, MSD, Lilly, Roche, Taiho Pharmaceutical, AstraZeneca and DKSH; consulting fees from Bristol Myers Squibb, Eisai, Taiho Pharmaceutical, Bayer, Merck, Novartis and MSD; research funding from Paxman and MSD; travel, accommodation funding support from Roche, AstraZeneca, Taiho Pharmaceutical and Eisai. PT has stock and other ownership interests in HealthSeq, research funding from Kyowa Hakko Kirin and Thermo Fisher Scientific, and patents/other intellectual property through the Agency for Science and Technology Research, Singapore (all outside the submitted work). CEC has received Honoraria and consulting fees from AstraZeneca, Roche/Genentech and Guardant Health AMEA; travel and accommodation support from Taiho Pharmaceutical. JC, LFK, MYS, BRA, BKJT, CBT, RYKT, JS, AS, KG, HLT, GC, HM, GKR, JHL, SS declared no conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the National Healthcare Group Domain Specific Ethics Review Board in 2015 (DSRB 2015/00209).